SCG2 and colorectal carcinoma: Our study suggests that SCG2 can be used as a new and effective indicator for predicting chemotherapy response, prognosis, and immune response in CRC patients, which means that SCG2 holds promise as a molecular marker to guide chemotherapy and immunotherapy in the clinical management of CRC.